Ziprasidone
- Generic Name
- Ziprasidone
- Brand Names
- Geodon, Zeldox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21ClN4OS
- CAS Number
- 146939-27-7
- Unique Ingredient Identifier
- 6UKA5VEJ6X
- Background
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...
- Indication
In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...
- Associated Conditions
- Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
- Associated Therapies
- -
Reducing the Abuse Liability of Prescription Opioids
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2020-10-14
- Target Recruit Count
- 15
- Registration Number
- NCT04587115
- Locations
- 🇺🇸
Westgate Pain Clinic, San Antonio, Texas, United States
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 350
- Registration Number
- NCT04446234
- Locations
- 🇨🇳
CHINA, Shanghai, Minhang, China
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 24
- Registration Number
- NCT03781115
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Banner University Medical Center, Phoenix, Arizona, United States
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2021-06-16
- Target Recruit Count
- 23
- Registration Number
- NCT03768726
- Locations
- 🇺🇸
Medical Research Group of Central Florida, Orange City, Florida, United States
🇺🇸Inova Clinical Trials and Research Centre, Fayetteville, Georgia, United States
🇺🇸Attalla Consultants, LLC dba Institute for Behavioral Medicine, Smyrna, Georgia, United States
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
Gene-by-Stress Interactions in Intervention Studies Significance
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 7
- Registration Number
- NCT03011645
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Yang Fude
- Target Recruit Count
- 1000
- Registration Number
- NCT02935998
- Locations
- 🇨🇳
Beijing Huilongguan Hospital, Beijing, Beijing, China
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Shanxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT02650102
- Locations
- 🇨🇳
First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study siteDrug: Paliperidone palmitateDrug: ChlorpromazineDrug: DroperidolDrug: FluphenazineDrug: HaloperidolDrug: LoxapineDrug: PerphenazineDrug: PimozideDrug: ProchlorperazineDrug: ThiothixeneDrug: ThioridazineDrug: TrifluoperazineDrug: AripiprazoleDrug: AsenapineDrug: ClozapineDrug: IloperidoneDrug: OlanzapineDrug: PaliperidoneDrug: QuetiapineDrug: RisperidoneDrug: Ziprasidone
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.